Biliary Tumor Market is segmented By Type (Extrahepatic Biliary Tumor, Intrahepatic Biliary Tumor), By Treatment (Surgery, Chemotherapy, Radiation, Targeted, Immunotherap ....
Market Size in USD
CAGR8.4%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 8.4% |
Market Concentration | High |
Major Players | AstraZeneca, Jiangsu HengRui Medicine, Amgen, Eli Lilly and Company, Pfizer |
The Global Biliary Tumor Market is estimated to be valued at USD 4.5 Bn in 2024 and is expected to reach USD 9.1 Bn by 2031, growing at a compound annual growth rate (CAGR) of 8.4% from 2024 to 2031.
The market for biliary tumors is expected to witness substantial growth over the forecast period. There is significant increase in risk factors such as obesity, alcohol consumption, and smoking which contributes to higher incidence of biliary tumors. Additionally, rising aging population also adds to the growth of this market. Furthermore, various initiatives undertaken by governments and non-profit organizations in creating awareness about cancer diagnosis and treatment supplements the market expansion. However, high cost of biliary tumor treatment and lack of effective therapeutics for late-stage tumors may hinder the market growth. Overall, increasing prevalence of biliary tumors due to changing lifestyle patterns will drive the demand in coming years.